Healthcare Policy, Market Access, Pricing and Reimbursement

Hungary’s Austerity Measures Impact Pharma – Drug Budget Planned to be Cut Almost by Half

Hungary’s Austerity Measures Impact Pharma – Drug Budget Planned to be Cut Almost by HalfHungary’s latest austerity plan, dubbed the Széll Kálmán Plan 2.0 — following on from last year’s first Széll Kálmán Plan, named after the nineteenth-century finance minister — was revealed towards the end of April. The plan aims to further reduce the country’s sizeable budget deficit, and includes a number of measures aimed at reducing pharmaceutical reimbursement spending further – prompting a stark warning from the Hungarian Innovative Pharma Association (IGY) of the likely withdrawal of an increasing number of medicines from the market, in response to the ever tightening regulatory situation.

Hungary’s Pharmaceutical reimbursement budget feels the pinch
With savings being sought everywhere and anywhere, the Hungarian government has come up with an extra 10 billion forint (USD45.3 million) cut in the pharma reimbursement budget of the National Health Insurance Fund (OEP) in 2012, to add to the 83 billion forint cut already envisaged in the first Széll Kálmán Plan, and another cut of 40-billion forint to the OEP’s budget in 2013…which in turn adds to the cut of around 120 billion forint planned last year.

Thus, when compared with the 2011 pharmaceutical reimbursement budget of the OEP – which reportedly reached 376 billion forint – the government is planning for a halving of the total sum available in 2013 – only 216 billion forint. Initial figures show that the budget cuts are some way behind their targets – but this is to be expected.

The second Széll Kálmán Plan still has to be approved by the European Commission, which is expected to give its decision by the end of May – and if the Commission should decide that the cuts are not sufficient, one-third of Hungary’s EU subsidies could be withheld – thus, it is an important test to pass.

A Series of Measures Rather than One Big Cut
No pharmaceutical market could withstand such a massive cut in the reimbursement budget without some severe, negative consequences. Under the first Széll Kálmán Plan, and in the new one, the Hungarian authorities have attempted to achieve the cuts through a series of measures rather than high-profile, across-the-board price cuts.

In 2011, these measures included:

  • An increase in the mandatory levy pharmaceutical companies pay on the sales of reimbursed drugs, from 12 to 20%
  • A doubling of the registration fee for pharmaceutical representatives
  • The introduction of a system of “blind” tenders for drugs reimbursed by the OEP, in October 2011


This year, among other measures, we have seen the introduction of a therapeutic / disease register system, under which drugs’ effectiveness is monitored and assessed, as well as the introduction of prescription by international non-proprietary name for cholesterol-lowering drugs (although use of brand names is permitted in certain cases). More measures, including the introduction of electronic prescriptions, are planned for next year.

Pharmacies Under Threat in Hungary
As well as the threats from the IGY of product withdrawals, many pharmacies are facing liquidity problems, as the blind tendering system brings prices down to a level at which profitability is minimal. Already, the drug cost-containment measures associated with the first and second Széll Kálmán plans are making Hungary’s Pharma Economic Act of 2007’s look mild by comparison.

About Brendan Melck

Brendan Melck is an analyst in the IHS Life Sciences practice. He covers the Central and Eastern Europe region (as well as Italy and Greece). With a background as a general business analyst covering this region, he has built a solid understanding of the pharmaceutical regulatory environment and the issues affecting the industry in these countries.

Discussion

No comments yet.

Leave a Comment

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Enter your email address to follow this blog and receive notifications of new posts by email.

Download extract from IHS Flexible Pricing strategies multi client study
Drug Price Erosion Multi Client Study extract download

About This Blog

In this blog, our experts share regular insights on the global life sciences industry. Join us as we look at issues in healthcare policy, market access, pricing and reimbursement and R&D. Comments are welcome!
40 countries covered. Download a sample chapter on Brazil
Download a complimentary white paper on market-access risk ratings
Download a sample of the primary research and analysis on French P&R reform

Follow IHS Life Sciences on Twitter

Follow

Get every new post delivered to your Inbox.

Join 305 other followers